RxDoctor Payments Data

Eric Johnson, MD

Interventional Cardiology · Oakland, CANPI 1043249642

Payments from drug & device makers

$40,840in general payments, 2019–2025

Across 83 payments — averaging $492.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$38K
  • Abbott$1K
  • Boston Scientific$595
  • Medtronic$237
  • Shockwave Medical, Inc$199
  • Philips North America LLC$84
  • plus $199 from 8 others

What the payments were for

  • Consulting fees$13,91534%
  • Speaking & faculty fees$22,10054%
  • Travel & lodging$2,3116%
  • Food & beverage$2,5146%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,840 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$418,097
Medicare patients
1,308
Services billed
3,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$378,807
XareltoRivaroxaban189$267,679
EntrestoSacubitril/Valsartan67$87,728
Repatha SureclickEvolocumab58$76,103
JardianceEmpagliflozin31$47,150
FarxigaDapagliflozin Propanediol20$18,607
Ezetimibe127$5,498
Atorvastatin Calcium392$4,056
Rosuvastatin Calcium204$3,348
Metoprolol Succinate250$3,243
Prasugrel Hcl11$2,745
Digoxin84$2,461
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$2,420
Bumetanide71$2,293
Carvedilol203$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$38,051$267,679189 claims
AstraZenecaFarxiga$12$18,60720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →